RxDoctor Payments Data

Mitzi Bales, MD

Family Medicine · Andover, KSNPI 1346205788

Payments from drug & device makers

$6,879in general payments, 2019–2025

Across 484 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$717
  • Novo Nordisk$689
  • AstraZeneca$624
  • GSK$434
  • Astellas Pharma US Inc$355
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,854100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,879 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$201,751
Medicare patients
240
Services billed
6,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$48,252
EliquisApixaban40$42,696
JardianceEmpagliflozin59$39,476
FarxigaDapagliflozin Propanediol33$24,439
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,802
Tresiba Flextouch U-200Insulin Degludec13$20,529
JanuviaSitagliptin Phosphate27$20,159
XareltoRivaroxaban17$14,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,810
MounjaroTirzepatide14$14,681
Lurasidone Hcl12$14,070
VascepaIcosapent Ethyl40$13,337
Breo ElliptaFluticasone/Vilanterol19$10,823
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$9,408
MyrbetriqMirabegron18$8,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$434$48,39693 claims
Novo NordiskOzempic$689$48,25238 claims
PfizerEliquis$353$42,69640 claims
Boehringer IngelheimJardiance$161$39,47659 claims
AstraZenecaFarxiga, Breztri Aerosphere$624$39,24956 claims
MerckJanuvia, Janumet Xr$236$26,49740 claims
Johnson & JohnsonXarelto$105$14,92117 claims
Lilly USA, LLCMounjaro$325$14,68114 claims
Astellas Pharma US IncMyrbetriq$355$8,42818 claims
Sumitomo Pharma America, Inc.Gemtesa$68$7,06516 claims
AbbVieSynthroid$1,250$2,59636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Andover

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →